Vaccinex Inc.
News
Vaccinex (NASDAQ:VCNX) Posts Earnings Results
Ticker Report Vaccinex (NASDAQ:VCNX - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($3.10) EPS for the quarter, reports. The business had revenue of $0.23 million...\n more…
VCNX Stock Earnings: Vaccinex Reported Results for Q2 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nVaccinex just reported results for the second quarter of 2024.\nThe post VCNX Stock Earnings: Vaccinex Reported Results for Q2 2024...\n more…
Vaccinex says Alzheimer's candidate buoyed by additional early-stage data
Seeking Alpha - Healthcare Vaccinex says Alzheimer's candidate buoyed by additional early-stage data...\n more…
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development Partnership
Globe Newswire Company reviews goals and significance of the study and outlines development strategy in Mild Cognitive Impairment due to Alzheimer's diseaseROCHESTER, N.Y., Aug. 14, 2024 (GLOBE NEWSWIRE...\n more…
Albert Friedberg Purchases 200,000 Shares of Vaccinex, Inc. (NASDAQ:VCNX) Stock
Ticker Report Vaccinex, Inc. (NASDAQ:VCNX - Get Free Report) Director Albert Friedberg purchased 200,000 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was bought at an...\n more…
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer's Disease
Globe Newswire Results affirm expectation of a novel mechanism of action targeting astrocyte activation to delay progression of Alzheimer's disease from early stage Mild Cognitive Impairment Findings echo previous...\n more…